Upcoming Virtual Event: VERSATILE-002 Trial Insights and Head and Neck Cancer Treatment Strategies

PDS Biotechnology Corporation, a company dedicated to advancing immunotherapy for cancer treatment and developing vaccines for infectious diseases, has announced details of an upcoming virtual event. The webinar, scheduled for May 8, 2024, will highlight the latest findings from the VERSATILE-002 Phase 2 clinical trial. This trial investigates the combination of Versamune® HPV and an immune checkpoint inhibitor in treating HPV16-positive head and neck squamous cell carcinoma.

The event will feature presentations by distinguished experts in the field. Dr. Jared Weiss, a professor at the University of North Carolina and principal investigator of the VERSATILE-002 trial, will discuss the trial's outcomes. Dr. Robert Haddad, a Harvard Medical School professor and a leading figure in head and neck cancer research, will address the current challenges in treating HPV-positive head and neck cancer. The session will be moderated by Dr. Kirk Shepard, PDS Biotech’s Chief Medical Officer, who will outline the company's future clinical strategies for the Versamune® HPV and PDS01ADC combination therapy.

PDS Biotechnology is committed to pioneering an innovative immunotherapy approach that targets cancer cells both internally and externally. The company's lead program combines PDS01ADC, an IL-12 fused antibody drug conjugate, with Versamune® HPV, a T-cell activator, along with a standard immune checkpoint inhibitor. Early data suggests that this dual-acting regimen could offer significant survival benefits and tumor reduction, with a favorable safety profile.

The company's Infectimune® platform has shown promise in inducing robust immune responses, including neutralizing antibodies and T-cell reactions, in pre-clinical studies. PDS Biotech aims to initiate a pivotal clinical trial in 2024 to further advance its lead program for advanced head and neck squamous cell cancers.

Dr. Jared Weiss is a renowned oncologist with a focus on personalized and adaptive immunotherapy. He has been instrumental in the development of several approved cancer treatments and is an advocate for cancer patients. Dr. Robert Haddad is a prominent researcher in head and neck cancer, known for his work in developing new therapeutic agents and conducting influential clinical trials.

PDS Biotechnology's mission is to transform cancer treatment by enhancing the immune system's ability to target and eliminate cancer cells. The company's innovative approach and dedication to clinical advancement underscore its commitment to improving patient outcomes in the fight against cancer.